300254 仟源医药
已收盘 09-21 15:00:00
资讯
新帖
简况
仟源医药(300254)披露2026年限制性股票激励计划获股东大会审议通过,9月4日股价上涨0.23%
证券之星 · 09-04
仟源医药(300254)披露2026年限制性股票激励计划获股东大会审议通过,9月4日股价上涨0.23%
股市必读:仟源医药新发布《国浩律师(上海)事务所关于仟源医药2026年第三次临时股东会之法律意见书》
证券之星 · 09-04
股市必读:仟源医药新发布《国浩律师(上海)事务所关于仟源医药2026年第三次临时股东会之法律意见书》
仟源医药(300254)披露2026年限制性股票激励计划草案,9月1日股价上涨1.57%
证券之星 · 09-01
仟源医药(300254)披露2026年限制性股票激励计划草案,9月1日股价上涨1.57%
仟源医药:公司将于2026年9月3日召开2026年第三次临时股东会
证券日报 · 09-01
仟源医药:公司将于2026年9月3日召开2026年第三次临时股东会
仟源医药(300254)披露2026年半年度报告,8月25日股价下跌3.04%
证券之星 · 08-25
仟源医药(300254)披露2026年半年度报告,8月25日股价下跌3.04%
仟源医药(300254)6月30日股东户数1.74万户,较上期减少7.38%
证券之星 · 08-25
仟源医药(300254)6月30日股东户数1.74万户,较上期减少7.38%
股市必读:仟源医药新发布《第六届董事会第七次会议决议公告》
证券之星 · 08-19
股市必读:仟源医药新发布《第六届董事会第七次会议决议公告》
股市必读:仟源医药新发布《第六届董事会第七次会议决议公告》
证券之星 · 08-18
股市必读:仟源医药新发布《第六届董事会第七次会议决议公告》
仟源医药(300254)披露2024年限制性股票激励计划第二个解除限售期解除限售股份上市流通提示性公告,7月22日股价下跌1.2%
证券之星 · 07-22
仟源医药(300254)披露2024年限制性股票激励计划第二个解除限售期解除限售股份上市流通提示性公告,7月22日股价下跌1.2%
仟源医药(300254)披露2024年限制性股票激励计划第二个解除限售期解除限售条件成就公告,7月16日股价上涨4.62%
证券之星 · 07-16
仟源医药(300254)披露2024年限制性股票激励计划第二个解除限售期解除限售条件成就公告,7月16日股价上涨4.62%
仟源医药(300254)披露2025年限制性股票激励计划预留授予登记完成公告,7月10日股价上涨3.65%
证券之星 · 07-10
仟源医药(300254)披露2025年限制性股票激励计划预留授予登记完成公告,7月10日股价上涨3.65%
仟源医药(300254)披露《一致行动协议》到期不再续签公告,7月7日股价下跌5.27%
证券之星 · 07-07
仟源医药(300254)披露《一致行动协议》到期不再续签公告,7月7日股价下跌5.27%
仟源医药(300254.SZ)子公司获得培哚普利氨氯地平片(Ⅱ)药品注册证书
智通财经 · 06-24
仟源医药(300254.SZ)子公司获得培哚普利氨氯地平片(Ⅱ)药品注册证书
股市必读:仟源医药(300254)5月22日披露最新机构调研信息
证券之星 · 05-25
股市必读:仟源医药(300254)5月22日披露最新机构调研信息
仟源医药(300254)披露向2025年限制性股票激励计划激励对象授予预留限制性股票的公告,5月20日股价下跌6.01%
证券之星 · 05-20
仟源医药(300254)披露向2025年限制性股票激励计划激励对象授予预留限制性股票的公告,5月20日股价下跌6.01%
仟源医药(300254)披露2025年年度股东会召开提示性公告,5月15日股价上涨0.28%
证券之星 · 05-15
仟源医药(300254)披露2025年年度股东会召开提示性公告,5月15日股价上涨0.28%
每周股票复盘:仟源医药(300254)股东户数降17.37%,一季净利跌67.83%
证券之星 · 05-03
每周股票复盘:仟源医药(300254)股东户数降17.37%,一季净利跌67.83%
仟源医药(300254)2026年一季报简析:净利润同比下降67.83%,应收账款上升
中金财经 · 04-29
仟源医药(300254)2026年一季报简析:净利润同比下降67.83%,应收账款上升
仟源医药(300254)披露回购注销2025年限制性股票激励计划部分限制性股票公告,4月28日股价上涨2.32%
证券之星 · 04-28
仟源医药(300254)披露回购注销2025年限制性股票激励计划部分限制性股票公告,4月28日股价上涨2.32%
图解仟源医药年报:第四季度单季净利润同比增长228.54%
证券之星 · 04-28
图解仟源医药年报:第四季度单季净利润同比增长228.54%
加载更多
公司概况
公司名称:
山西仟源医药集团股份有限公司
所属行业:
医药制造业
上市日期:
2011-08-19
主营业务:
山西仟源医药集团股份有限公司的主营业务是医药、保健食品的研发、生产、销售、医疗健康服务及商业业务等。公司的主要产品是磷霉素氨丁三醇散、盐酸坦索罗辛缓释胶囊、依巴斯汀片、酒石酸伐尼克兰片、维生素AD滴剂、盐酸氨溴索分散片、蒙脱石散、盐酸氟西汀胶囊、盐酸西那卡塞片、阿哌沙班片、利伐沙班片、盐酸氨基葡萄糖(原料药)、保灵孕宝口服液、基因保存服务。
发行价格:
13.00
{"stockData":{"symbol":"300254","market":"SZ","secType":"STK","nameCN":"仟源医药","latestPrice":9.04,"timestamp":1789974189000,"preClose":8.67,"halted":0,"volume":9916500,"delay":0,"changeRate":0.0427,"floatShares":227000000,"shares":256999999,"eps":0.1118,"marketStatus":"已收盘","change":0.37,"latestTime":"09-21 15:00:00","open":8.66,"high":9.06,"low":8.66,"amount":88910600,"amplitude":0.0461,"askPrice":9.05,"askSize":995,"bidPrice":9.04,"bidSize":3,"shortable":0,"etf":0,"ttmEps":0.1118,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790040600000},"marketStatusCode":5,"adr":0,"adjPreClose":8.67,"symbolType":"stock","openAndCloseTimeList":[[1789954200000,1789961400000],[1789966800000,1789974000000]],"highLimit":9.54,"lowLimit":7.8,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":257208563,"isCdr":false,"pbRate":4.96,"roa":"--","peRate":80.858676,"roe":"1.14%","epsLYR":0.1024,"committee":-0.660594,"marketValue":2325000000,"turnoverRate":0.0436,"status":0,"floatMarketCap":2055000000},"requestUrl":"/m/hq/s/300254","defaultTab":"news","newsList":[{"id":"2664333428","title":"仟源医药(300254)披露2026年限制性股票激励计划获股东大会审议通过,9月4日股价上涨0.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664333428","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664333428?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:41","pubTimestamp":1788514879,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘,仟源医药报收于8.7元,较前一交易日上涨0.23%,最新总市值为22.38亿元。公司于近日披露《2026年第三次临时股东会决议公告》。会议由副董事长钟海荣主持,出席会议的股东共108人,代表股份占公司总股本的11.9657%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400031636.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0042","BK0239","BK0028","BK0077","300254","BK0114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664080650","title":"股市必读:仟源医药新发布《国浩律师(上海)事务所关于仟源医药2026年第三次临时股东会之法律意见书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664080650","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664080650?lang=zh_cn&edition=full","pubTime":"2026-09-04 02:03","pubTimestamp":1788458596,"startTime":"0","endTime":"0","summary":"截至2026年9月3日收盘,仟源医药报收于8.68元,下跌1.14%,换手率3.06%,成交量6.97万手,成交额6052.1万元。公司公告汇总:2026年限制性股票激励计划内幕信息知情人在自查期间均无买卖公司股票行为。交易信息汇总资金流向9月3日主力资金净流出176.33万元,占总成交额2.91%;游资资金净流出235.15万元,占总成交额3.89%;散户资金净流入411.48万元,占总成交额6.8%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400002414.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0042","BK0239","BK0028","BK0077","300254","BK0114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664857143","title":"仟源医药(300254)披露2026年限制性股票激励计划草案,9月1日股价上涨1.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664857143","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664857143?lang=zh_cn&edition=full","pubTime":"2026-09-01 22:47","pubTimestamp":1788274031,"startTime":"0","endTime":"0","summary":"截至2026年9月1日收盘,仟源医药报收于9.06元,较前一交易日上涨1.57%,最新总市值为23.3亿元。该股当日开盘8.92元,最高9.08元,最低8.84元,成交额达8919.78万元,换手率为4.37%。上述议案需经出席会议有效表决权股份总数的三分之二以上通过,并对中小投资者单独计票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100043302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0046","BK0042","300254","BK0114","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664585758","title":"仟源医药:公司将于2026年9月3日召开2026年第三次临时股东会","url":"https://stock-news.laohu8.com/highlight/detail?id=2664585758","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664585758?lang=zh_cn&edition=full","pubTime":"2026-09-01 21:47","pubTimestamp":1788270420,"startTime":"0","endTime":"0","summary":"9月1日,仟源医药发布公告称,公司将于2026年9月3日召开2026年第三次临时股东会。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-01/doc-iniqitru8352444.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-01/doc-iniqitru8352444.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0077","300254","BK0114","BK0239","BK0042","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662541736","title":"仟源医药(300254)披露2026年半年度报告,8月25日股价下跌3.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662541736","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662541736?lang=zh_cn&edition=full","pubTime":"2026-08-25 18:46","pubTimestamp":1787654815,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘,仟源医药报收于9.25元,较前一交易日下跌3.04%,最新总市值为23.79亿元。该股当日开盘9.47元,最高9.54元,最低9.05元,成交额达2.79亿元,换手率为13.31%。公司于近日披露《2026年半年度报告》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500039712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0046","BK0028","BK0114","BK0239","300254","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662219738","title":"仟源医药(300254)6月30日股东户数1.74万户,较上期减少7.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662219738","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662219738?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:52","pubTimestamp":1787651540,"startTime":"0","endTime":"0","summary":"证券之星消息,近日仟源医药披露,截至2026年6月30日公司股东户数为1.74万户,较3月31日减少1389.0户,减幅为7.38%。在化学制药行业个股中,仟源医药股东户数低于行业平均水平,截至6月30日,化学制药行业平均股东户数为3.68万户。从股价来看,2026年3月31日至2026年6月30日,仟源医药区间跌幅为28.99%,在此期间股东户数减少1389.0户,减幅为7.38%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500037616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","300254","BK0028","BK0114","BK0046","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660849912","title":"股市必读:仟源医药新发布《第六届董事会第七次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660849912","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660849912?lang=zh_cn&edition=full","pubTime":"2026-08-19 01:36","pubTimestamp":1787074569,"startTime":"0","endTime":"0","summary":"公司公告汇总第六届董事会第七次会议决议公告仟源医药第六届董事会第七次会议审议通过《2026年限制性股票激励计划(草案)》及其摘要、《2026年限制性股票激励计划实施考核管理办法》、激励对象黄乐群累计获授股份超公司总股本1%、提请股东大会授权董事会办理本次股权激励相关事宜,以及召开2026年第三次临时股东大会的议案。前三项议案因涉及关联董事回避表决,需提交股东大会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900001480.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0239","BK0077","BK0046","300254","BK0114","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660439055","title":"股市必读:仟源医药新发布《第六届董事会第七次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660439055","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660439055?lang=zh_cn&edition=full","pubTime":"2026-08-18 01:00","pubTimestamp":1786986048,"startTime":"0","endTime":"0","summary":"公司公告汇总第六届董事会第七次会议决议公告仟源医药第六届董事会第七次会议审议通过《2026年限制性股票激励计划(草案)》及其摘要、《2026年限制性股票激励计划实施考核管理办法》、激励对象黄乐群累计获授股份超公司总股本1%、提请股东大会授权董事会办理本次股权激励相关事宜,以及召开2026年第三次临时股东大会的议案。前三项议案因涉及关联董事回避表决,需提交股东大会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800001345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0114","BK0042","BK0239","BK0046","300254","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653766127","title":"仟源医药(300254)披露2024年限制性股票激励计划第二个解除限售期解除限售股份上市流通提示性公告,7月22日股价下跌1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653766127","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653766127?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:38","pubTimestamp":1784731095,"startTime":"0","endTime":"0","summary":"近日,仟源医药发布《关于2024年限制性股票激励计划第二个解除限售期解除限售股份上市流通提示性公告》。公告显示,公司于2026年7月16日召开第六届董事会第六次会议,审议通过2024年限制性股票激励计划第二个解除限售期解除限售条件成就的议案。本次解除限售的激励对象共46人,解除限售股份198万股,占公司总股本的0.77%。个人绩效考核均合格,解除限售比例为100%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200047679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0077","300254","BK0114","BK0239","BK0042","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651844029","title":"仟源医药(300254)披露2024年限制性股票激励计划第二个解除限售期解除限售条件成就公告,7月16日股价上涨4.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651844029","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651844029?lang=zh_cn&edition=full","pubTime":"2026-07-16 22:16","pubTimestamp":1784211380,"startTime":"0","endTime":"0","summary":"截至2026年7月16日收盘,仟源医药报收于9.29元,较前一交易日上涨4.62%,最新总市值为23.89亿元。仟源医药于2026年7月16日发布《关于2024年限制性股票激励计划第二个解除限售期解除限售条件成就的公告》。本次符合解除限售条件的激励对象共46人,解除限售数量为198万股,占公司总股本的0.77%。本次解除限售尚需办理相关手续并履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600040125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","300254","BK0028","BK0114","BK0046","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650960136","title":"仟源医药(300254)披露2025年限制性股票激励计划预留授予登记完成公告,7月10日股价上涨3.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650960136","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650960136?lang=zh_cn&edition=full","pubTime":"2026-07-10 22:45","pubTimestamp":1783694715,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘,仟源医药报收于8.24元,较前一交易日上涨3.65%,最新总市值为21.1亿元。公告显示,公司已完成2025年限制性股票激励计划预留授予登记工作。限售期分别为自登记完成之日起12个月和24个月,分两个批次各解除限售50%。业绩考核目标为2026年、2027年营业收入或扣非净利润较2024年增长率分别不低于18.02%、27.57%或71.04%、133.96%。本次授予后公司总股本增至257,208,563股,募集资金用于补充流动资金。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000044953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300254","BK0114","BK0077","BK0046","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649365179","title":"仟源医药(300254)披露《一致行动协议》到期不再续签公告,7月7日股价下跌5.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649365179","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649365179?lang=zh_cn&edition=full","pubTime":"2026-07-07 22:57","pubTimestamp":1783436236,"startTime":"0","endTime":"0","summary":"截至2026年7月7日收盘,仟源医药报收于8.09元,较前一交易日下跌5.27%,最新总市值为20.72亿元。公告显示,公司股东黄乐群、赵群及江苏维嘉科技技术有限公司于2023年6月30日签署的《一致行动协议》有效期至2026年6月30日,经协商到期不再续签,一致行动关系终止。协议终止后,黄乐群、赵群所持股份不再合并计算,各自独立行使股东权利。截至公告日,赵群持股15,781,792股,占总股本6.16%;黄乐群持股5,265,060股,占总股本2.06%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700042236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0028","BK0042","300254","BK0046","BK0239","BK0114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645471895","title":"仟源医药(300254.SZ)子公司获得培哚普利氨氯地平片(Ⅱ)药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2645471895","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645471895?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:39","pubTimestamp":1782290356,"startTime":"0","endTime":"0","summary":"智通财经APP讯,仟源医药 发布公告,近日,公司之子公司杭州仟源保灵药业有限公司收到国家药品监督管理局签发的“培哚普利氨氯地平片(Ⅱ)”《药品注册证书》。该药品属于化学药品4类仿制药,依据国内仿制药审评相关政策,批准后视同通过一致性评价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458057.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300254","BK0028","BK0239","BK0046","BK0114","BK0077","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638307314","title":"股市必读:仟源医药(300254)5月22日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2638307314","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638307314?lang=zh_cn&edition=full","pubTime":"2026-05-25 03:46","pubTimestamp":1779651972,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘,仟源医药报收于13.09元,上涨2.35%,换手率4.3%,成交量9.72万手,成交额1.26亿元。公司在北美设立子公司,是为从事高端仿制药、改良新药、精麻类药物及吸入制剂等特殊制剂的研发及商业化运营,并逐步布局创新药研发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500001557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0114","BK0042","BK0239","BK0046","300254","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636810426","title":"仟源医药(300254)披露向2025年限制性股票激励计划激励对象授予预留限制性股票的公告,5月20日股价下跌6.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636810426","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636810426?lang=zh_cn&edition=full","pubTime":"2026-05-20 17:30","pubTimestamp":1779269446,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘,仟源医药报收于13.13元,较前一交易日下跌6.01%,最新总市值为33.62亿元。近日,仟源医药发布《关于向2025年限制性股票激励计划激励对象授予预留限制性股票的公告》。本次授予的限售期为自登记完成之日起12个月、24个月,解除限售比例分别为50%、50%。本次授予符合公司2025年第三次临时股东会审议通过的激励计划规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000032706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300254","BK0114","BK0042","BK0046","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635033016","title":"仟源医药(300254)披露2025年年度股东会召开提示性公告,5月15日股价上涨0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635033016","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635033016?lang=zh_cn&edition=full","pubTime":"2026-05-15 22:41","pubTimestamp":1778856074,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘,仟源医药报收于14.44元,较前一交易日上涨0.28%,最新总市值为36.97亿元。该股当日开盘14.28元,最高14.5元,最低14.04元,成交额达1.59亿元,换手率为4.93%。近日,山西仟源医药集团股份有限公司发布《关于召开2025年年度股东会的提示性公告》。公告显示,公司将于2026年5月19日召开2025年年度股东会,会议采取现场表决与网络投票相结合的方式。股权登记日为2026年5月12日。中小投资者表决结果将单独计票并披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500044368.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0114","300254","BK0042","BK0077","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632973672","title":"每周股票复盘:仟源医药(300254)股东户数降17.37%,一季净利跌67.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632973672","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2632973672?lang=zh_cn&edition=full","pubTime":"2026-05-03 04:29","pubTimestamp":1777753748,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,仟源医药报收于13.5元,较上周的11.94元上涨13.07%。本周,仟源医药4月30日盘中最高价报13.64元。股本股东变化截至2026年3月31日,公司股东户数为1.88万户,较12月31日减少3956.0户,减幅为17.37%。立信会计师事务所对山西仟源医药截至2025年12月31日的财务报告内部控制有效性进行审计,认为公司在所有重大方面保持了有效的财务报告内部控制。山西仟源医药2025年度财务报表经审计,审计意见为标准无保留意见。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300000979.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300254","BK0114","BK0077","BK0239","BK0046","BK0042","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631555286","title":"仟源医药(300254)2026年一季报简析:净利润同比下降67.83%,应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2631555286","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2631555286?lang=zh_cn&edition=full","pubTime":"2026-04-29 09:07","pubTimestamp":1777424864,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期仟源医药发布2026年一季报。截至本报告期末,公司营业总收入1.74亿元,同比下降4.37%,归母净利润334.23万元,同比下降67.83%。本报告期仟源医药应收账款上升,应收账款同比增幅达40.34%。去年的净利率为6.48%,算上全部成本后,公司产品或服务的附加值一般。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202604/29/20260429691256.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202604/29/20260429691256.png"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260429/32187656.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300254"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630377906","title":"仟源医药(300254)披露回购注销2025年限制性股票激励计划部分限制性股票公告,4月28日股价上涨2.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630377906","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630377906?lang=zh_cn&edition=full","pubTime":"2026-04-28 18:07","pubTimestamp":1777370847,"startTime":"0","endTime":"0","summary":"截至2026年4月28日收盘,仟源医药报收于12.33元,较前一交易日上涨2.32%,最新总市值为31.57亿元。公司于近日披露《关于回购注销2025年限制性股票激励计划部分限制性股票的公告》。公告显示,山西仟源医药集团股份有限公司于2026年4月26日召开第六届董事会第四次会议,审议通过关于回购注销2025年限制性股票激励计划部分限制性股票的议案。本次回购注销完成后,公司总股本将由256,058,563股变更为256,008,563股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800054060.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0239","BK0046","BK0114","BK0077","BK0028","300254"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630319893","title":"图解仟源医药年报:第四季度单季净利润同比增长228.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630319893","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630319893?lang=zh_cn&edition=full","pubTime":"2026-04-28 01:06","pubTimestamp":1777309579,"startTime":"0","endTime":"0","summary":"证券之星消息,仟源医药2025年年报显示,当年度公司主营收入8.71亿元,同比上升2.86%;归母净利润2485.09万元,同比下降41.1%;扣非净利润3175.54万元,同比上升25.87%;其中2025年第四季度,公司单季度主营收入2.59亿元,同比上升9.05%;单季度归母净利润252.35万元,同比上升228.54%;单季度扣非净利润1422.84万元,同比上升796.76%;负债率63.82%,投资收益397.15万元,财务费用2151.25万元,毛利率67.38%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800003044.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300254"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1790002205348,"stockEarnings":[{"period":"1week","weight":0.026},{"period":"1month","weight":-0.0069},{"period":"3month","weight":-0.0236},{"period":"6month","weight":-0.2415},{"period":"1year","weight":-0.2089},{"period":"ytd","weight":-0.1433}],"compareEarnings":[{"period":"1week","weight":0.0061},{"period":"1month","weight":0.0045},{"period":"3month","weight":-0.0437},{"period":"6month","weight":-0.0114},{"period":"1year","weight":0.0209},{"period":"ytd","weight":-0.0144}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山西仟源医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"17431人(较上一季度减少7.38%)","perCapita":"13042股","listingDate":"2011-08-19","address":"山西省大同市云州区大同经济技术开发区生物科技创新产业园翠微街2号","registeredCapital":"25720万元","survey":" 山西仟源医药集团股份有限公司的主营业务是医药、保健食品的研发、生产、销售、医疗健康服务及商业业务等。公司的主要产品是磷霉素氨丁三醇散、盐酸坦索罗辛缓释胶囊、依巴斯汀片、酒石酸伐尼克兰片、维生素AD滴剂、盐酸氨溴索分散片、蒙脱石散、盐酸氟西汀胶囊、盐酸西那卡塞片、阿哌沙班片、利伐沙班片、盐酸氨基葡萄糖(原料药)、保灵孕宝口服液、基因保存服务。","listedPrice":13},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"仟源医药(300254)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供仟源医药(300254)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"仟源医药,300254,仟源医药股票,仟源医药股票老虎,仟源医药股票老虎国际,仟源医药行情,仟源医药股票行情,仟源医药股价,仟源医药股市,仟源医药股票价格,仟源医药股票交易,仟源医药股票购买,仟源医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"仟源医药(300254)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供仟源医药(300254)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}